What You Should Know:
– Deloitte, a global leader in professional services, has unveiled Atlas AI, a groundbreaking addition to its Quartz AI™ suite, marking a significant leap forward in life sciences and healthcare (LSHC).
– Built on the NVIDIA AI and NVIDIA Omniverse™ platforms, Atlas AI empowers scientists with novel tools to expedite drug discovery and bring life-saving treatments to market faster.
Harnessing the Power of Generative AI
Atlas AI boasts a unique arsenal of AI technologies:
– Generative AI models: Made accessible through BioNeMo, these models facilitate the generation of new drug candidates with enhanced properties.
– Knowledge representation and reasoning: This technology unlocks deeper data insights by connecting and interpreting scientific knowledge.
– Custom protein and chemoinformatics LLMs: These specialized language models analyze protein structures and predict drug-target interactions, paving the way for more precise drug design.
Beyond Drug Discovery
Atlas AI is just the beginning for Deloitte’s LSHC ambitions. Future iterations will incorporate additional applications like:
– Precision Medicine: Tailoring treatments to individual patients based on their unique genetic and molecular profiles.
– Voice of the Patient Insight: Capturing and analyzing patient feedback to improve treatment plans and healthcare outcomes.
Dan Ferrante, Deloitte’s AI leader for innovation and R&D, highlights the transformational potential of Atlas AI: “It represents the true power of Generative AI and LLMs, enabling deeper data insights and seamless human-machine collaboration for real-world impact. Through its no-code interface, Atlas AI puts powerful tools directly in the hands of scientists, saving valuable research time.”
